英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
tenetur查看　tenetur　在百度字典中的解释百度英翻中〔查看〕
tenetur查看　tenetur　在Google字典中的解释Google英翻中〔查看〕
tenetur查看　tenetur　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
    Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
  • Update 2025: Management of Non‑Small-Cell Lung Cancer - PMC
    Introduction Lung cancer has remained the leading cause of cancer-related mortality worldwide since the 1950s, posing a significant global health challenge [1] NSCLC, which constitutes the majority of lung cancer cases, has historically been associated with poor outcomes due to its often late diagnosis and limited treatment options [2]
  • FDA Approves Alectinib for ALK-Positive Lung Cancer
    Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
  • FDA approves alectinib as adjuvant treatment for ALK-positive . . .
    FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
  • Non-Small Cell Lung Cancer - Guidelines Detail - NCCN
    Archived NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 7 2025
  • Lorlatinib Versus Crizotinib in Patients With Advanced ALK . . .
    Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung cancer (NSCLC) in the phase III CROWN study Here, we report long-term outcomes from CROWN after 5 years of follow-up
  • Molecular Glue Degrader TRI-611 Receives FDA Fast Track for . . .
    The Food and Drug Administration (FDA) has granted Fast Track designation to TRI-611 for the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) TRI-611 is an oral, brain-penetrant molecular glue degrader designed to selectively eliminate ALK fusion proteins in patients with ALK+ NSCLC
  • Alectinib in combination with bevacizumab as first-line . . .
    Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy This work reports a phase 2 trial
  • ALK and Lung Cancer - American Lung Association
    ALK stands for anaplastic lymphoma kinase It was originally described in lymphoma, but most ALK-positive cancers are in non-small cell lung cancer
  • Real-world treatment sequencing and effectiveness of second . . .
    With multiple targeted therapies approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), it is increasingly important to understand outcomes with various sequences of next-generation ALK tyrosine kinase inhibitors (TKIs) We describe contemporary sequencing patterns and treatment effectiveness of first-line (1L) and second-line (2L) treatments in





中文字典-英文字典  2005-2009